Martin Schrappe

Summary

Affiliation: University of Kiel
Country: Germany

Publications

  1. doi Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient
    Martin Schrappe
    Department of Pediatrics at the Christian Albrechts University of Kiel, University Medical Center Schleswig Holstein, Kiel, Germany
    Hematology Am Soc Hematol Educ Program 2012:137-42. 2012
  2. pmc Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
    Thorsten Simon
    Children s Hospital, University of Cologne, Cologne, Germany
    BMC Cancer 11:21. 2011
  3. doi Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia
    Martin Schrappe
    Department of General Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, 24105 Kiel, Germany
    Radiat Prot Dosimetry 132:130-3. 2008
  4. doi Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols
    Martin Stanulla
    Department of Pediatrics, University Children s Hospital, Kiel, Germany
    Blood 114:1314-8. 2009
  5. pmc IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol
    Petra Dörge
    Department of Pediatrics, University Medical Centre Schleswig Holstein, Kiel, Germany
    Haematologica 98:428-32. 2013
  6. doi Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
    Martin Schrappe
    Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Blood 118:2077-84. 2011
  7. doi Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia
    Barbara Meissner
    Department of Pediatrics, University Hospital Schleswig Holstein, Kiel, Germany
    Hum Mol Genet 23:590-601. 2014
  8. ncbi Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia
    Gunnar Cario
    Department of Pediatrics, University Hospital Schleswig Holstein, Campus Kiel, Schwanenweg 20, 24105 Kiel, Germany
    Ann Hematol 87:709-16. 2008
  9. doi Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol
    Gunnar Cario
    Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Arnold Heller Strasse 3, Kiel, Germany
    Blood 115:5393-7. 2010
  10. doi Treatment of childhood acute lymphoblastic leukemia
    Martin Stanulla
    Department of Pediatrics, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Semin Hematol 46:52-63. 2009

Collaborators

Detail Information

Publications14

  1. doi Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient
    Martin Schrappe
    Department of Pediatrics at the Christian Albrechts University of Kiel, University Medical Center Schleswig Holstein, Kiel, Germany
    Hematology Am Soc Hematol Educ Program 2012:137-42. 2012
    ..Clinical application of such sophisticated tools in the stratification and treatment of ALL requires reliable, reproducible, and quality-assured methods to ensure patient safety...
  2. pmc Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
    Thorsten Simon
    Children s Hospital, University of Cologne, Cologne, Germany
    BMC Cancer 11:21. 2011
    ..We applied metronomic chemotherapy in the prospective NB90 trial and monoclonal anti-GD2-antibody (MAB) ch14.18 in the NB97 trial. Here, we present the long term outcome data of the patient cohort...
  3. doi Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia
    Martin Schrappe
    Department of General Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, 24105 Kiel, Germany
    Radiat Prot Dosimetry 132:130-3. 2008
    ..This may facilitate innovative chemotherapy approaches and a more rational use of allogeneic haematopoetic stem cell transplantation. In addition, genetic signatures of treatment response or failure have been identified...
  4. doi Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols
    Martin Stanulla
    Department of Pediatrics, University Children s Hospital, Kiel, Germany
    Blood 114:1314-8. 2009
    ..Thus, TPMT does not play a major role in the etiology of secondary malignant neoplasm after treatment for childhood ALL, according to Berlin-Frankfurt-Münster strategies...
  5. pmc IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol
    Petra Dörge
    Department of Pediatrics, University Medical Centre Schleswig Holstein, Kiel, Germany
    Haematologica 98:428-32. 2013
    ..Thus, IKZF1 deletion is an independent predictor of treatment outcome and a strong candidate marker for integration in future treatment stratification strategies on ALL-BFM protocols. Clinicaltrials.gov identifier: NCT00430118...
  6. doi Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
    Martin Schrappe
    Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Blood 118:2077-84. 2011
    ..clinicaltrials.gov; "Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia," protocol identification #NCT00430118 for BFM and #NCT00613457 for AIEOP...
  7. doi Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia
    Barbara Meissner
    Department of Pediatrics, University Hospital Schleswig Holstein, Kiel, Germany
    Hum Mol Genet 23:590-601. 2014
    ....
  8. ncbi Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia
    Gunnar Cario
    Department of Pediatrics, University Hospital Schleswig Holstein, Campus Kiel, Schwanenweg 20, 24105 Kiel, Germany
    Ann Hematol 87:709-16. 2008
    ..Leukemic cells of patients with PPR are characterized by gene expression pattern which are similar to those of resistant cells persisting under glucocorticoid treatment...
  9. doi Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol
    Gunnar Cario
    Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Arnold Heller Strasse 3, Kiel, Germany
    Blood 115:5393-7. 2010
    ..The assessment of CRLF2 aberrations may therefore serve as new stratification tool in Berlin-Frankfurt-Münster-based protocols by identifying additional high-risk patients who may benefit from an intensified and/or targeted treatment...
  10. doi Treatment of childhood acute lymphoblastic leukemia
    Martin Stanulla
    Department of Pediatrics, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Semin Hematol 46:52-63. 2009
    ....
  11. pmc Outcomes after induction failure in childhood acute lymphoblastic leukemia
    Martin Schrappe
    Department of Pediatrics, University Medical Center Schleswig Holstein, Christian Albrechts University, Kiel, Germany
    N Engl J Med 366:1371-81. 2012
    ..Failure of remission-induction therapy is a rare but highly adverse event in children and adolescents with acute lymphoblastic leukemia (ALL)...
  12. ncbi Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma
    Anna Czajczynska
    Division of Stem Cell Transplantation and Immunotherapy, University of Kiel, Kiel, Germany
    Biol Blood Marrow Transplant 19:1632-7. 2013
    ..Intense reinduction therapy followed by reduced-intensity BEAM-alemtuzumab conditioning and allogeneic HSCT is effective and offers curative potential for patients with advanced T cell lymphomas, even for those not in remission. ..
  13. ncbi Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
    Anja Möricke
    Department of Pediatrics, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Blood 111:4477-89. 2008
    ..2% (+/- 3.2%). Compared without previous trial ALL-BFM 90, consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients...
  14. ncbi Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95
    Andre Schrauder
    Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    J Clin Oncol 24:5742-9. 2006
    ..The role of hematopoietic stem-cell transplantation (SCT) in first complete remission (CR1) for children with very high-risk (VHR) acute lymphoblastic leukemia (ALL) is still under critical discussion...